Table of Contents
1. Preface
2. Assumptions and Research Methodology
3. Executive Summary : Global Market
4. Market Overview
5. Market Outlook
6. Global Market Analysis and Forecast, By Drug Class
- 6.1. Anti-platelet Medications
- 6.2. Cholesterol Lowering Medications
- 6.3. Fibric Acid and Omega-3 Fatty Acid Derivatives
- 6.4. Beta Blockers
- 6.5. Angiotensin-Converting Enzyme (ACE) Inhibitors
- 6.6. Calcium Channel Blockers
- 6.7. Diuretics
- 6.8. Others
7. Global Market Analysis and Forecast, By Distribution Channel
- 7.1. Retail Pharmacies
- 7.2. Hospital Pharmacies
- 7.3. Online Pharmacies
8. Global Market Analysis and Forecast, By Region
- 8.1. North America
- 8.2. Europe
- 8.3. Asia Pacific
- 8.4. Latin America
- 8.5. Middle East & Africa
9. North America Market Analysis and Forecast
10. Europe Market Analysis and Forecast
11. Asia Pacific Market Analysis and Forecast
12. Latin America Market Analysis and Forecast
13. Middle East & Africa Market Analysis and Forecast
14. Competition Landscape
- 14.1. GlaxoSmithKline Plc
- 14.2. Sanofi
- 14.3. Hoffmann-La Roche Ltd
- 14.4. Bayer AG
- 14.5. Novartis AG
- 14.6. Merck & Co., Inc. (Merck Sharp & Dohme Corp)
- 14.7. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 14.8. Mylan N.V.
- 14.9. Amgen Inc.
- 14.10. Pfizer, Inc.
List of Tables
Table 01: Atherosclerosis Pipeline Analysis
Table 02: Atherosclerosis Pipeline Analysis
Table 03: Global Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 04: Global Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 05: Global Market Revenue (US$ Mn) Forecast, by Region, 2023 to 2033
Table 06: North America Market Revenue (US$ Mn) Forecast, by Drug Class 2023 to 2033
Table 07: North America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 08: North America Market Revenue (US$ Mn) Forecast, by Country, 2023 to 2033
Table 09: Europe Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 10: Europe Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 11: Europe Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 12: Asia Pacific Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 13: Asia Pacific Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 14: Asia Pacific Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
Table 15: Latin America Market Revenue (US$ Mn) Forecast, by Drug Class 2023 to 2033
Table 16: Latin America Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 17: Latin America Market Revenue (US$ Mn) Forecast, by Country / Sub-region, 2023 to 2033
Table 18: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Drug Class, 2023 to 2033
Table 19: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2023 to 2033
Table 20: Middle East & Africa Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2023 to 2033
List of Figures
Figure 01: Global Market Revenue (US$ Mn) and Distribution (%), by Region, 2023 and 2033
Figure 02: Global Market Revenue (US$ Mn), by Drug Class, 2023
Figure 03: Global Market Revenue Share Analysis, by Drug Class, 2023
Figure 04: Market Overview
Figure 05: Global Market Revenue Share, by Drug Class, 2023
Figure 06: Global Market Revenue Share, by Distribution Channel, 2023
Figure 07: Global Market Revenue Share, by Region, 2023
Figure 08: Global Market Revenue (US$ Mn) Forecast, 2023 to 2033
Figure 09: Global Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 10: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Anti-platelet Medications, 2023 to 2033
Figure 11: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Cholesterol Lowering Medications, 2023 to 2033
Figure 12: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibric Acid and Omega-3 Fatty Acid Derivatives, 2023 to 2033
Figure 13: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Beta Blockers, 2023 to 2033
Figure 14: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Angiotensin-converting Enzyme (ACE) Inhibitors, 2023 to 2033
Figure 15: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Calcium Channel Blockers, 2023 to 2033
Figure 16: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Diuretics, 2023 to 2033
Figure 17: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2023 to 2033
Figure 18: Global Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 19: Global Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 20: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth(%) Projection, by Retail Pharmacies, 2023 to 2033
Figure 21: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023 to 2033
Figure 22: Global Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023 to 2033
Figure 23: Global Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 24: Global Market Revenue Share Analysis, by Region, 2023 and 2033
Figure 25: Global Market Attractiveness Analysis, by Region, 2023 to 2033
Figure 26: North America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 27: North America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 28: North America Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 29: North America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 30: North America Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 31: North America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 32: North America Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 33: Europe Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 34: Europe Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 35: Europe Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 36: Europe Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 37: Europe Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 38: Europe Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 39: Europe Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 40: Asia Pacific Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 41: Asia Pacific Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 42: Asia Pacific Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 43: Asia Pacific Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 45: Asia Pacific Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 47: Latin America Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 48: Latin America Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 49: Latin America Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 50: Latin America Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 51: Latin America Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 52: Latin America Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 53: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 54: Middle East & Africa Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023 to 2033
Figure 55: Middle East & Africa Market Revenue Share Analysis, by Drug Class, 2023 and 2033
Figure 56: Middle East & Africa Market Attractiveness Analysis, by Drug Class, 2023 to 2033
Figure 57: Middle East & Africa Market Revenue Share Analysis, by Distribution Channel, 2023 and 2033
Figure 58: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2023 to 2033
Figure 59: Middle East & Africa Market Revenue Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 60: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2023 to 2033
Figure 61: Market Position Analysis, 2023, by Tier and Size of the Company
Figure 62: GlaxoSmithKline plc (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 63: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region/Country, 2023
Figure 64: GlaxoSmithKline plc Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 66: Sanofi (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 65: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 68: Sanofi Revenue Breakdown of Net Sales (%), by Pharmaceutical Business segment, 2023
Figure 69: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 70: F. Hoffmann-La Roche Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 71: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Region, 2023
Figure 72: F. Hoffmann-La Roche Ltd Breakdown of Net Sales (%), by Pharmaceutical Division, 2023
Figure 73: F. Hoffmann-La Roche Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 74: Bayer AG, Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 75: Bayer AG Breakdown of Net Sales (%), by Region, 2023
Figure 76: Bayer AG Revenue Breakdown of Net Sales (%), by Business segment, 2023
Figure 77: Bayer AG, pharmaceutical segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 79: Novartis AG Breakdown of Net Sales (%) of Innovative Medicines Business Segment, by Region/Country, 2023
Figure 80: Novartis AG Revenue Breakdown of Net Sales (%), by Innovative Medicines Segment, 2023
Figure 81: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 82: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 83: Merck & Co., Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 84: Merck & Co., Inc. Revenue Breakdown of Net Sales (%), by Segment, 2023
Figure 85: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 86: Johnson & Johnson Pharmaceutical Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 87: Johnson & Johnson Breakdown of Net Sales (%), of Pharmaceutical Segment by Region/Country, 2023
Figure 88: Johnson & Johnson Revenue Breakdown of Net Sales (%), by Pharmaceutical Segment, 2023
Figure 89: Johnson & Johnson, Pharmaceutical Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2023 to 2023
Figure 90: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 91: Mylan N.V. R&D Expenses (US$ Mn), 2023 to 2023
Figure 92: Mylan N.V. Breakdown of Net Sales, by Region, 2023
Figure 93: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 94: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2023
Figure 95: Amgen Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), by Segment 2014 to 2023
Figure 96: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Figure 97: Pfizer, Inc. Breakdown of Net Sales, by Geography, 2023
Figure 98: Pfizer, Inc. Breakdown of Net Sales, by Business Segment (%), 2023
Figure 99: Pfizer, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018 to 2023
Who worked on this report
Preview the report firsthand - request a free sample
Free SampleGet the brochure for pricing and purchase details
Download PDF